Friday, July 11, 2025 | 02:04 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

In race to stop Covid-19, Indian drugmakers to conduct clinical trials

Glenmark, Zydus Cadila to start trials in May

Civil defence officials wear protective suits to help a man who was lying on the roadside near Hebbal flyover during a nationwide lockdown imposed in the wake of novel coronavirus pandemic, in Bengaluru. Photo: PTI
premium

Civil defence officials wear protective suits to help a man who was lying on the roadside near Hebbal flyover during a nationwide lockdown imposed in the wake of novel coronavirus pandemic, in Bengaluru. Photo: PTI

Sohini DasSamreen Ahmad Mumbai | Bengaluru
If the trials go along expected lines, we will soon have an antiviral drug (Favipiravir) for Covid-19 patients in the market.
Glenmark Pharmaceuticals is all set to start clinical trials on mild to moderate coronavirus-positive patients in May.
 
Meanwhile, several other Indian firms are stepping up efforts to start clinical trials on other drug candidates — such as biologic drug Interferon alfa-2b and antiviral drug Remdesivir.
 
Cadila Healthcare (Zydus Cadila) will start clinical trials on Interferon alfa-2b, a drug that it already makes commercially for Hepatitis C, for the novel coronavirus.